Dr. Ariela Hoxha is a leading consultant physician and rheumatologist in the Department of Medicine at the University of Padua, where she heads the Immunothrombosis Clinic. Her expertise lies in diagnosing and managing inflammatory and autoimmune rheumatic diseases, particularly antiphospholipid antibody syndrome and autoimmune congenital heart block. Dr. Hoxha’s research has significantly advanced the understanding of these conditions, with numerous publications co-authored and authored by her focusing on their clinical features and treatments. She has played a crucial role in preventing maternal and fetal complications for women with high-risk antiphospholipid antibody syndrome and has developed a treatment protocol for congenital heart block due to anti-Ro/La antibodies, integrating plasmapheresis, intravenous immunoglobulins, and betamethasone. Her investigations investigations into antiphospholipid antibodies have made innovative contributions to understanding the clinical significance of phosphatidylserine/prothrombin and anti-domain antibodies. In collaboration with other Italian rheumatology centers, Dr. Hoxha is studying complement activation markers in various clinical subsets of antiphospholipid syndrome and correlating these with clinical characteristics and antibody profiles. Currently, she is focused on the potential of the Damage Index for Antiphospholipid Syndrome in predicting patient mortality, further enriching her contributions to the field.